HTG Expands Data Analytics Capabilities for Customers with the Release of HTG EdgeSeq Reveal Data Analytics Software Version 1.2.0

July 8, 2019 at 8:00 AM EDT

TUCSON, Ariz., July 08, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the release of its HTG EdgeSeqTM Reveal data analytics software, version 1.2.0. HTG EdgeSeq Reveal is a powerful software product that can enable customers to streamline their analysis of samples processed on the HTG EdgeSeq platform. The new release contains enhanced functionality enabling data analysis from the HTG EdgeSeq Precision Immuno‑Oncology Panel, the HTG EdgeSeq Oncology Biomarker Panel, and the newly released HTG EdgeSeq Mouse mRNA Tumor Response Panel. Together with HTG EdgeSeq molecular profiling assays, customers using the new HTG EdgeSeq Reveal software product will have the ability to more rapidly draw conclusions from their data and to generate charts representing their discoveries.

“Our customers asked for a powerful data analysis tool for use with our research use only (RUO) assays; we listened and delivered. HTG EdgeSeq Reveal allows our customers to quickly assess the quality and biological relevance of their data generated from our HTG EdgeSeq RUO assays,” said John Lubniewski, President and CEO of HTG. “With this new release, we have expanded the applications and utility of data analytics capabilities, including pathway assessment tools. Our innovative HTG EdgeSeq Reveal data analysis suite is a scalable, flexible data product that we believe will continue to expand with new assays and applications to support HTG’s growing product portfolio.”

About HTG
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.

Safe Harbor Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits that the HTG EdgeSeq Reveal software product will provide to our customers and the expected scalability, flexibility and expansion of the HTG EdgeSeq Revealdata analysis suite. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that our HTG EdgeSeq Reveal data analytics software version 1.2.0 may not provide the expected benefits; risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


Ashley R. Robinson
LifeSci Advisors, LLC
Phone: (617) 535-7742

HTG logo

Source: HTG Molecular Diagnostics, Inc.